Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
or

Protagonist Therapeutics Inc (PTGX)

Protagonist Therapeutics Inc (PTGX)
45.85 +0.05 (+0.11%) 04/22/25 [NASDAQ]
N/A x N/A N/A x N/A
Realtime by (Cboe BZX)
N/A x N/A N/A x N/A
Realtime 45.78 -0.07 (-0.15%) 17:23 ET
Quote Overview for Tue, Apr 22nd, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
45.42
Day High
46.41
Open 46.00
Previous Close 45.80 45.80
Volume 775,100 775,100
Avg Vol 1,263,255 1,263,255
Stochastic %K 68.35% 68.35%
Weighted Alpha +29.12 +29.12
5-Day Change +0.82 (+1.82%) +0.82 (+1.82%)
52-Week Range 24.22 - 60.60 24.22 - 60.60
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,811,387
  • Shares Outstanding, K 61,384
  • Annual Sales, $ 434,430 K
  • Annual Income, $ 275,190 K
  • EBIT $ 253 M
  • EBITDA $ 247 M
  • 60-Month Beta 2.30
  • Price/Sales 6.54
  • Price/Cash Flow 10.25
  • Price/Book 4.08

Options Overview Details

View History
  • Implied Volatility 56.95% ( +0.51%)
  • Historical Volatility 48.21%
  • IV Percentile 28%
  • IV Rank 27.44%
  • IV High 138.06% on 02/21/25
  • IV Low 26.27% on 06/03/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 25
  • Volume Avg (30-Day) 800
  • Put/Call OI Ratio 0.73
  • Today's Open Interest 8,329
  • Open Int (30-Day) 18,720

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.50
  • Number of Estimates 6
  • High Estimate -0.22
  • Low Estimate -0.71
  • Prior Year 3.26
  • Growth Rate Est. (year over year) -115.34%

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.60 +15.78%
on 04/09/25
Period Open: 52.65
53.70 -14.62%
on 03/24/25
-6.80 (-12.92%)
since 03/21/25
3-Month
33.70 +36.05%
on 02/25/25
Period Open: 36.88
60.60 -24.34%
on 03/12/25
+8.97 (+24.32%)
since 01/22/25
52-Week
24.22 +89.31%
on 04/26/24
Period Open: 26.61
60.60 -24.34%
on 03/12/25
+19.24 (+72.30%)
since 04/22/24

Most Recent Stories

More News
Protagonist Therapeutics Reports Granting of Inducement Award

NEWARK, CA / ACCESS Newswire / April 16, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company"), a clinical-stage biopharmaceutical company pioneering the discovery and development of peptide-based...

PTGX : 45.85 (+0.11%)
Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill

84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16

PTGX : 45.85 (+0.11%)
Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025

Past Winners include Waymo, Nvidia, Duolingo, and Novo Nordisk, among others

PTGX : 45.85 (+0.11%)
Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis

Clinical response rate of 63.5% and clinical remission rate of 30.2% achieved at Week 12 with the highest dose, which continued to improve through Week 28

PTGX : 45.85 (+0.11%)
Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis

Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) treated with icotrokinra achieved completely clear skin (IGA 0) at Week 24 in Phase 3 ICONIC-LEAD study

PTGX : 45.85 (+0.11%)
Protagonist Therapeutics: Q4 Earnings Snapshot

Protagonist Therapeutics: Q4 Earnings Snapshot

PTGX : 45.85 (+0.11%)
Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

$165.0 million icotrokinra (formerly JNJ-2113) milestone earned in Q4 2024, received in January 2025

PTGX : 45.85 (+0.11%)
Protagonist to Host Investor Event with KOL Insights on Polycythemia Vera (PV) and the Hepcidin Mimetic Rusfertide in New York on February 6, 2025

NEWARK, CALIFORNIA / ACCESS Newswire / January 29, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company")will host an in-person and virtual investor event on Thursday, February 6, 2025,...

PTGX : 45.85 (+0.11%)
Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CALIFORNIA / ACCESSWIRE / January 6, 2025 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on January 2, 2025, it issued inducement awards to Newman Yeilding, M.D., upon his appointment...

PTGX : 45.85 (+0.11%)
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025

NEWARK, CA / ACCESSWIRE / December 19, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide...

PTGX : 45.85 (+0.11%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. The Company's initial lead product candidates consists of PTG-100 and...

See More

Key Turning Points

3rd Resistance Point 47.36
2nd Resistance Point 46.88
1st Resistance Point 46.37
Last Price 45.85
1st Support Level 45.38
2nd Support Level 44.90
3rd Support Level 44.39

See More

52-Week High 60.60
Fibonacci 61.8% 46.70
Last Price 45.85
Fibonacci 50% 42.41
Fibonacci 38.2% 38.12
52-Week Low 24.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro